BCM
VIVO

Bluefin Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Bluefin Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-26,554
Closed -$545K – 770
2015
Q4 		$545K Buy
+26,554
New +$509K 0.04% 291

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Bluefin Capital Management's VIVO Position: Q1 2016 in Review

Bluefin Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2016, closing a stake of 26,554 shares — an estimated $545K sold.

Bluefin Capital Management first reported a position in VIVO in Q4 2015 and held it in 1 quarter. The position peaked at $545K in Q4 2015. 172 funds tracked by Wall St. Rank hold VIVO as of Q1 2016.

  • Bluefin Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2016 after selling out during the quarter.
  • Bluefin Capital Management sold 26,554 Meridian Bioscience Inc shares in Q1 2016, an estimated $545K.
  • Bluefin Capital Management first reported a position in Meridian Bioscience Inc in Q4 2015 and held it in 1 quarter.
  • Bluefin Capital Management's Meridian Bioscience Inc position peaked at $545K in Q4 2015.
  • 172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2016.

Based on Bluefin Capital Management's 13F filing for Q1 2016, filed 16 May 2016.